Real-World Data on Subsequent Therapy for First-Line Osimertinib-Induced Pneumonitis: Safety of EGFR-TKI Rechallenge (Osi-risk Study TORG-TG2101)

Naoya Nishioka, Hisao Imai, Masahiro Endo, Akifumi Notsu, Kosei Doshita, Satoshi Igawa, Hiroshi Yokouchi, Takashi Ninomiya, Takaaki Tokito, Sayo Soda, Takasato Fujiwara, Tetsuhiko Asao, Shinji Nakamichi, Takahisa Kawamura, Minehiko Inomata, Kazuhisa Nakashima, Kentaro Ito, Yasuhiro Goto, Yukihiro Umeda, Soichi Hirai, Ryota Ushio, Keiki Yokoo, Takayuki Takeda, Tomoya Fukui, Masashi Ishihara, Takashi Osaki, Sousuke Kubo, Takumi Fujiwara, Chie Yamamoto, Takeshi Tsuda, Nobumasa Tamura, Shinobu Hosokawa, Yusuke Chihara, Satoshi Ikeda, Naoki Furuya, Yoshiro Nakahara, Satoru Miura, Hiroaki Okamoto

Open source

DOI: 10.1007/s11523-024-01048-x
Published: 2024-04-13
Container: Targeted Oncology
Publisher: Springer Science and Business Media LLC
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s11523-024-01048-x,
  title = {Real-World Data on Subsequent Therapy for First-Line Osimertinib-Induced Pneumonitis: Safety of EGFR-TKI Rechallenge (Osi-risk Study TORG-TG2101)},
  author = {Naoya Nishioka and Hisao Imai and Masahiro Endo and Akifumi Notsu and Kosei Doshita and Satoshi Igawa and Hiroshi Yokouchi and Takashi Ninomiya and Takaaki Tokito and Sayo Soda and Takasato Fujiwara and Tetsuhiko Asao and Shinji Nakamichi and Takahisa Kawamura and Minehiko Inomata and Kazuhisa Nakashima and Kentaro Ito and Yasuhiro Goto and Yukihiro Umeda and Soichi Hirai and Ryota Ushio and Keiki Yokoo and Takayuki Takeda and Tomoya Fukui and Masashi Ishihara and Takashi Osaki and Sousuke Kubo and Takumi Fujiwara and Chie Yamamoto and Takeshi Tsuda and Nobumasa Tamura and Shinobu Hosokawa and Yusuke Chihara and Satoshi Ikeda and Naoki Furuya and Yoshiro Nakahara and Satoru Miura and Hiroaki Okamoto},
  year = {2024},
  journal = {Targeted Oncology},
  doi = {10.1007/s11523-024-01048-x},
  url = {https://doi.org/10.1007/s11523-024-01048-x}
}

RIS

TY  - JOUR
TI  - Real-World Data on Subsequent Therapy for First-Line Osimertinib-Induced Pneumonitis: Safety of EGFR-TKI Rechallenge (Osi-risk Study TORG-TG2101)
AU  - Naoya Nishioka
AU  - Hisao Imai
AU  - Masahiro Endo
AU  - Akifumi Notsu
AU  - Kosei Doshita
AU  - Satoshi Igawa
AU  - Hiroshi Yokouchi
AU  - Takashi Ninomiya
AU  - Takaaki Tokito
AU  - Sayo Soda
AU  - Takasato Fujiwara
AU  - Tetsuhiko Asao
AU  - Shinji Nakamichi
AU  - Takahisa Kawamura
AU  - Minehiko Inomata
AU  - Kazuhisa Nakashima
AU  - Kentaro Ito
AU  - Yasuhiro Goto
AU  - Yukihiro Umeda
AU  - Soichi Hirai
AU  - Ryota Ushio
AU  - Keiki Yokoo
AU  - Takayuki Takeda
AU  - Tomoya Fukui
AU  - Masashi Ishihara
AU  - Takashi Osaki
AU  - Sousuke Kubo
AU  - Takumi Fujiwara
AU  - Chie Yamamoto
AU  - Takeshi Tsuda
AU  - Nobumasa Tamura
AU  - Shinobu Hosokawa
AU  - Yusuke Chihara
AU  - Satoshi Ikeda
AU  - Naoki Furuya
AU  - Yoshiro Nakahara
AU  - Satoru Miura
AU  - Hiroaki Okamoto
PY  - 2024
JO  - Targeted Oncology
DO  - 10.1007/s11523-024-01048-x
UR  - https://doi.org/10.1007/s11523-024-01048-x
ER  -

APA

Nishioka, N., Imai, H., Endo, M., Notsu, A., Doshita, K., Igawa, S., Yokouchi, H., Ninomiya, T., Tokito, T., Soda, S., Fujiwara, T., Asao, T., Nakamichi, S., Kawamura, T., Inomata, M., Nakashima, K., Ito, K., Goto, Y., Umeda, Y., Hirai, S., Ushio, R., Yokoo, K., Takeda, T., Fukui, T., Ishihara, M., Osaki, T., Kubo, S., Fujiwara, T., Yamamoto, C., Tsuda, T., Tamura, N., Hosokawa, S., Chihara, Y., Ikeda, S., Furuya, N., Nakahara, Y., Miura, S., & Okamoto, H. (2024). Real-World Data on Subsequent Therapy for First-Line Osimertinib-Induced Pneumonitis: Safety of EGFR-TKI Rechallenge (Osi-risk Study TORG-TG2101). Targeted Oncology. https://doi.org/10.1007/s11523-024-01048-x

Source records

crossref · retrieved 2026-09-26T21:46:06.425Z